We examined the relationship between plasma adipokine concentrations and ultrasound measures of vascular health in 100 HIV-infected adults on antiretroviral therapy. Leptin was positively correlated with flow-mediated dilation of the brachial artery and negatively with carotid intima-media thickness. These relationships were independent of traditional risk factors and trunk fat in women but not men. Neither adiponectin nor resistin was associated with either measure of vascular health.
Changes in body fat composition in HIV-infected patients on antiretroviral therapy (ART) are associated with adverse cardiometabolic risk factors [1] and altered levels of circulating adipocytokines [2, 3] . Adipokines are known to exert direct effects on endothelial cells and vascular function in vitro [4] [5] [6] [7] , although larger epidemiologic studies have failed to demonstrate a consistent relationship between plasma adipokine concentrations and cardiovascular disease (CVD) in humans [8, 9] . Little is known about the relationship between adipokines and CVD risk in HIV. In this study, we sought to examine the relationship between adipokines and measures of vascular health among HIV-infected patients on stable ART. Plasma concentrations of leptin, adiponectin, and resistin were measured by ELISA in 100 HIV-infected adults, on stable ART, with HIV-1 RNA less than 1000 copies/ml and low-density lipoprotein (LDL)-cholesterol 130 mg/ dl or less. The study was approved by the Institutional Review Board of University Hospitals Case Medical Center (Cleveland, Ohio, USA) and written informed consent was obtained from each subject. Scatter plots, t-tests, Spearman correlations, and multivariable linear regression were used to examine the association of adipokines with regional fat distribution (trunk and limb fat), pericardial and periaortic fat volumes, common carotid artery intima-media thickness (CIMT), and endothelial function measured by brachial artery flowmediated dilation (FMD). Fat distribution was measured by dual-energy X-ray absorptiometry (DEXA) in the anteroposterior view using Lunar Prodigy Advance (GE Healthcare, Waukesha, Wisconsin, USA). Pericardial and thoracic periaortic fat volumes were quantified as described previously [10] from a computed tomography scan of the chest (Somatom Sensation 64; Siemens Medical Solutions, USA). Semiautomated edge detection software (Medical Imaging Applications LLC, Coralville, lowa, USA) was used to measure mean-mean common carotid artery far wall CIMT [11] . Flow-dependent endothelial function testing was performed by brachial artery ultrasound using a 5-min forearm occlusion method as previously described [12] . All vascular ultrasound and perivascular fat measurements were performed by a single blinded reader (C.T.L.). Nonnormally distributed variables (including the adipokine concentrations, FMD, CIMT, and perivascular fat volumes) were log-transformed for all analyses. All statistical tests were two-sided with a 0.05 significance level.
Overall, the study population was 77% men and 70% African-American. Median [interquartile range (IQR)] age and BMI were 47 (42-53) years and 27 (24-31) kg/m 2 , respectively; although BMI was higher in women compared with men [32 (26-37) kg/m 2 versus 26 (23-29) kg/m 2 , P < 0.001]. Compared with men, women had 2.2-fold higher limb fat and 1.6-fold higher trunk fat (P < 0.001) by DEXA. Overall, median (IQR) CD4 cell count of 633 (453-854) cells/ml and 81% had HIV-1 RNA less than 50 copies/ml. Fifty percent were on a protease inhibitor; however, only 4% were currently taking a thymidine analog nucleoside reverse transcriptase inhibitor. One quarter of participants had metabolic syndrome [13] . Thirty percent of women were treated with antihypertensive medication, 4% were taking aspirin, and 83% had HIV-1 RNA less than 50 copies/ml. Of the women with detectable viremia (n ¼ 4), all had less than 200 copies/ml. Leptin concentration was much higher in women compared with men [median (IQR) 55 (21-73) versus 7.0 (2.9-13)ng/ml, P < 0.001], whereas adiponectin and resistin concentrations were similar (P ¼ 0.844 and P ¼ 0.345, respectively). Leptin concentration was strongly and linearly correlated with both trunk fat (r ¼ 0.836, P < 0.0001) and limb fat (r ¼ 0.862, P < 0.0001), although correlations with epicardial and periaortic fat were weaker (r ¼ 0.399, P < 0.0001 and r ¼ 0.267, P ¼ 0.007, respectively). Adiponectin was negatively correlated with trunk fat (r ¼ À0.336, P ¼ 0.0006), epicardial fat (r ¼ À0.300, P ¼ 0.047), and periaortic fat (r ¼ À0.200, P ¼ 0.0008); but not limb fat (P ¼ 0.108). No correlation was observed between resistin concentration and regional or perivascular fat volumes (P > 0.20).
Leptin concentration was positively correlated with FMD (r ¼ 0.336, P ¼ 0.0006) and negatively with CIMT (r ¼ À0.304, P ¼ 0.002). These relationships were stronger in women compared with men ( Fig. 1a ). In multivariable models that adjusted for age, smoking, trunk fat, and baseline brachial artery diameter (for FMD only), leptin remained positively associated with FMD and negatively associated with CIMT in women (P ¼ 0.018 and P ¼ 0.022, respectively) but not men (P ¼ 0.565 and P ¼ 0.748, respectively). Neither adiponectin nor resistin was associated with FMD or CIMT ( Fig. 1b and c).
In this contemporary cohort of HIV-infected men and women on ART without clinical lipoatrophy and with limited use of thymidine analogs, higher plasma leptin concentration appears to be associated with healthier arterial structure and function measured by carotid ultrasound and brachial artery FMD. In women, these relationships were independent of several traditional CVD risk factors and visceral adiposity. These results suggest the possibility of an obesity paradox in this population of HIVinfected women with regards to CVD risk.
Although obesity is generally associated with poor vascular health and CVD risk in the general population [14, 15] , examples of CVD obesity paradoxes do exist [16, 17] . Some prior studies of HIV-infected patients have reported similarly paradoxical results. In the Women's Interagency Health Study, higher BMI was associated with lower prevalence of CIMT more than 1.5 mm despite a positive association with overall mean CIMT [18] . The Study of Fat Redistribution and Metabolic Change in HIV infection did not report associations of IMTwith measures of adiposity [19] ; however, in separate analyses, higher subcutaneous adipose tissue (SAT) was associated with higher leptin, paradoxically higher adiponectin [2] , and lower Framingham risk [20] . In a study of endothelial function that included a small number of women (n ¼ 27), both SAT and leptin concentration were positively correlated with FMD, although the relationship was attenuated in multivariable models [21] . Finally, we have previously described a positive correlation between BMI and FMD independent of other risk factors in a majority male population [22] .
This study is limited by a relatively small sample size and cross-sectional design, although these limitations are shared by most studies of endothelial function in HIV. Therefore, our study was not powered to explore all possible confounders. Our participants had little clinical lipoatrophy and favorable LDL cholesterol levels, which reflects current trends in the HIV-infected population; however, this makes comparisons with older studies more difficult.
In conclusion, previous studies in HIV have linked SAT to higher leptin and lower cardiovascular risk [2, 20] . In this ultrasound study of vascular health, these relationships appear to persist in an obese HIV-infected population with a low prevalence of clinical lipoatrophy, particularly among women. This unexpected observation merits further investigation in longitudinal studies.
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This project was supported by an award from the National Institutes of Health NR012642. The content is solely the The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12 IU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (n U 9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12 IU/ml at W24 (P < 0.001). No grade 3-4 dermatological sideeffects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients.
Direct antiviral agents (DAAs) targeting hepatitis C virus (HCV) protease activity have triggered a major shift in treating HCV genotype 1 (G1) infection. In HCV-HIV coinfected patients, boceprevir (BOC) or telaprevir (TVR) with pegylated-interferon (pegylated-interferon and ribavirin) has led to a 30% increase in sustained virological response rates in treatment-naive patients [1, 2] . However, these results may not apply to more difficult-to-treat populations, such as cirrhotic, HIVinfected patients failing previous treatment with pegylated-interferon and ribavirin [3] . The primary objective of the study herein was to evaluate the efficacy and tolerance during 24 weeks of TVR-based tritherapy in HIV-HCV G1-coinfected patients previously treated with pegylated-interferon and ribavirin.
From December 2011 to May 2012, HIV-HCV G1-infected patients receiving TVR [1125 mg three times daily (t.i.d.) with efavirenz (EFV); 750 mg t.i.d. with raltegravir (RAL), atazanavir (ATZ), or without antiretroviral (ARV) therapy], PegIFNa2 (180 mg/week), and ribavirin (1000 mg/day < 75 kg, 1200 mg/day !75 kg) were recruited from two outpatient clinics in Paris, France (Hôpital Saint-Antoine, Hôpital Pitié-Salpêtrière). All patients had provided signed informed consent, in accordance with the Helsinki Declaration. At inclusion, response to previous pegylated-interferon and ribavirin treatment was defined according to European AIDS Clinical Society guidelines [4] . HCV-RNA was measured using the Abbott RealTime HCV assay (detection limit: <12 IU/ml) and Il28B polymorphism using the LightMix Il28B kit. In patients failing TVRbased therapy [5] , amino acid substitutions in HCV protease were examined by direct sequencing following PCR-amplification of the NS3 encoding region, between nucleotides 3309 and 4054 [6] . A sequence editing program was used (Seqscape; Applied Biosciences, Les Ulis, France) and substitutions associated with TVR resistance further confirmed with the 'Geno2pheno (hcv)' tool (http://www.geno2pheno.org). In ARVtreated patients, EFV/ATZ/RAL trough concentrations were measured after a 12-h fast by high-performance liquid chromatography at TVR initiation (C min0 ), and then twice after TVR initiation (week 4 ¼ C min1 , week All laboratory adverse events were grade 3-4: anemia (hemoglobin <8 g/dl), thrombopenia (platelet count <50000/ml), leukopenia (<2000/ml), and neutropenia (<750/ml). 1 Comparing patients with versus without response at week 24 (W24); significance determined using a Kruskal-Wallis test for continuous variables and Pearson x 2 test or Fisher's exact test for categorical variables.
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12 ¼ C min2 ). Variation in concentrations before and after TVR initiation was defined as [(C min1 þC min2 )/2]/C min0 . Adverse events were graded according to AIDS Clinical Trial Group classification [7] . Platelet, leukocyte or erythropoietin growth factors, and blood transfusions were permitted.
The virological endpoints were the proportions of patients with undetectable HCV-RNA at W2, W4, W12, and W24. Analysis on treatment response was intention-to-treat (ITT). Determinants of HCV-RNA less than 12 UI/ml at W24 were compared between treatment response groups, while no P value adjustments for multiple comparisons were made. Statistical analysis was performed using STATA (v11.2; College Station, Texas, USA) and significance was determined as P < 0.05.
Baseline characteristics are presented in Table 1 , stratified by W24 response. A previous null response was observed in 50% of patients and 75% were cirrhotic. The proportion of patients with undetectable HCV-RNA was 35.3% at W2, 55.0% at W4, 65.0% at W12, and 55.0% at W24; and 50% had extended rapid virological response (undetectable HCV-RNA at W4 and W12) [4] . Following stopping rules, nine patients ended treatment early: W4 ¼ 3, W12 ¼ 3, W24 ¼ 3. One patient terminated treatment at W8 due to psychiatric adverse events despite rapid virological success. Undetectable HCV-RNA at W12 was the only significant determinant among those with versus without treatment response (P <0.001).
All nine patients with virological failure harbored genotype 1a, with TVR-resistant variants appearing at the time of failure. Six double amino acid substitutions at positions V36MþR155K were the only mutations observed prior to W24. HCV population sequencing for those harboring resistant variants at the end of TVR treatment showed different mutation patterns with a potentially lower genetic barrier to TVR resistance (V36LþQ80KþR155K, R155K, or V36MþT54A).
HIV-RNAwas detectable (>20 copies/ml) for three ARVtreated patients at baseline (range: 31-42 copies/ml), 0 at W12, and one at W24 (50 copies/ml The following grade 3-4 adverse events occurred during treatment: thrombopenia (20%), leukopenia (20%), anemia (5%), and neutropenia (5%). Accordingly, a substantial drop in platelet count and hemoglobin was observed, requiring the use of growth factors in 11 patients (erythropoietine: n ¼ 11, eltrombopag: n ¼ 5)
and iterative blood transfusions in two patients. No grade 3-4 dermatological side-effects were reported.
In this well defined cohort, 55% responded to TVRcontaining tritherapy after 24 weeks. This rate is lower than that found in previous reports in HIV-HCVcoinfected patients, with rates reaching upward of 71% in treatment-naive and less frequently cirrhotic patients [8] .
In HCV-G1-monoinfected patients with higher prevalence of bridging fibrosis or cirrhosis, both early and W24 response rates in previous partial or nonresponders were closer to what was observed in our study [9, 10] . Smaller studies have reported no difference in early treatment response according to HIV status [11] . Recent drugs, such as sofosbuvir, have also shown similar earlytreatment HCV kinetics between treatment-naive HIV-HCV and HCV-infected patients [12] . Patients experiencing virological failure exhibited the V36Mþ R155K double mutant, common in genotype 1a-infected individuals experiencing 'on-treatment' failure [13, 14] . As expected, no 1b subtype-infected patient selected this mutation. Although baseline resistance was not assessed, it is rather uncommon and cannot rule out TVR therapeutic success [15, 13] . Hematologic tolerance also appeared to be reasonable, as both rates of grade 3-4 hematological adverse events and/or use of growth factors seemed to be lower than those in cirrhotic HCV G1-monoinfected patients [1, 10, 16] . Importantly, no grade 3 or 4 rash was reported in our study, compared to 7.4% among HCV-monoinfected patients [16] and a 5% discontinuation rate due to rashes [10] . Better TVR tolerance among HIV-HCV-coinfected patients may be due to the lack of immune-mediated skin reactions via HIV-induced immunosuppression [17, 18] . Taken together, HIV coinfection is probably not a detrimental factor toward virological response to DAAs.
In conclusion, combined TVR-PR exhibited comparatively good efficacy and tolerability, to monoinfected patients, in a difficult-to-treat population of HIV-infected patients with chronic G1 hepatitis C. Notwithstanding the small number of patients, this population is generally excluded from clinical trials, bringing into light barriers to current anti-HCV therapy. As HIV-infected, cirrhotic patients failing previous HCV therapy have a high risk of developing end-stage liver disease and may not be able to wait for newer drugs to become available, TVR may represent an appropriate therapeutic strategy.
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